CERUS CORP (CERS) Stock Fundamental Analysis
USA - NASDAQ:CERS - US1570851014 - Common Stock
1.51 USD
+0.01 (+0.67%)
1.5116 USD
+0 (+0.11%)
Taking everything into account, CERS scores 3 out of 10 in our fundamental rating. CERS was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. CERS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
CERS had negative earnings in each of the past 5 years.
CERS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CERS's Return On Assets of -8.86% is fine compared to the rest of the industry. CERS outperforms 62.63% of its industry peers.
With a Return On Equity value of -34.06%, CERS perfoms like the industry average, outperforming 53.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.86% | ||
| ROE | -34.06% | ||
| ROIC | N/A |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CERS's Gross Margin of 60.94% is fine compared to the rest of the industry. CERS outperforms 62.11% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
2. Health
2.1 Basic Checks
CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CERS has more shares outstanding
The number of shares outstanding for CERS has been increased compared to 5 years ago.
CERS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.68, we must say that CERS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.68, CERS is doing worse than 69.47% of the companies in the same industry.
The Debt to FCF ratio of CERS is 24.80, which is on the high side as it means it would take CERS, 24.80 years of fcf income to pay off all of its debts.
CERS has a Debt to FCF ratio of 24.80. This is in the better half of the industry: CERS outperforms 70.53% of its industry peers.
CERS has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.02, CERS is doing worse than 76.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 24.8 | ||
| Altman-Z | -4.68 |
ROIC/WACCN/A
WACC8.69%
2.3 Liquidity
CERS has a Current Ratio of 2.00. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS has a Current ratio of 2.00. This is in the lower half of the industry: CERS underperforms 65.26% of its industry peers.
A Quick Ratio of 1.35 indicates that CERS should not have too much problems paying its short term obligations.
CERS has a Quick ratio of 1.35. This is in the lower half of the industry: CERS underperforms 63.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
Looking at the last year, CERS shows a quite strong growth in Revenue. The Revenue has grown by 11.25% in the last year.
CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%
3.2 Future
CERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.85% yearly.
The Revenue is expected to grow by 14.35% on average over the next years. This is quite good.
EPS Next Y-8.95%
EPS Next 2Y17.22%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue Next Year18.38%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CERS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CERS is cheaper than 71.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 84.57 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CERS's earnings are expected to grow with 28.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.22%
EPS Next 3Y28.85%
5. Dividend
5.1 Amount
No dividends for CERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.51
+0.01 (+0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners72.59%
Inst Owner Change0.14%
Ins Owners2.97%
Ins Owner Change1.65%
Market Cap289.47M
Revenue(TTM)216.39M
Net Income(TTM)-18879000
Analysts80
Price Target4.76 (215.23%)
Short Float %6.03%
Short Ratio8.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.16%
Min EPS beat(2)-6.95%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)12.58%
Min EPS beat(4)-6.95%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)21.86%
EPS beat(12)7
Avg EPS beat(12)8.29%
EPS beat(16)11
Avg EPS beat(16)13.28%
Revenue beat(2)0
Avg Revenue beat(2)-10%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)-5.44%
Revenue beat(4)1
Avg Revenue beat(4)-5.47%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-6.36%
Revenue beat(12)3
Avg Revenue beat(12)-5.39%
Revenue beat(16)7
Avg Revenue beat(16)-1.44%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.9%
Revenue NQ rev (1m)-3.33%
Revenue NQ rev (3m)-0.64%
Revenue NY rev (1m)-2.42%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.34 | ||
| P/FCF | 84.57 | ||
| P/OCF | 50.7 | ||
| P/B | 5.22 | ||
| P/tB | 5.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.02
FCFY1.18%
OCF(TTM)0.03
OCFY1.97%
SpS1.13
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.86% | ||
| ROE | -34.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.94% | ||
| FCFM | 1.58% |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 24.8 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 163.87% | ||
| Cap/Sales | 1.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | -4.68 |
F-Score5
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-8.95%
EPS Next 2Y17.22%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%
Revenue Next Year18.38%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
EBIT growth 1Y19.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year159.92%
EBIT Next 3Y65.7%
EBIT Next 5YN/A
FCF growth 1Y113.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.78%
OCF growth 3YN/A
OCF growth 5YN/A